Comparison of the Effects of Prophylactic and Therapeutic Administrations on Peripheral Neuropathy in Streptozotocin-Diabetic Rats with Gliclazide or Methylcobalamin

Abstract Objective To observe the differences in curative effects between prophylactic and therapeutic administrations of Gliclazide (GLZ) or Methylcobalamin (MCA) on diabetic peripheral neuropathy in rats. Methods GLZ (25 mg/kg/day) or MCA (175 μg/kg/day) was orally administrated prophylactically to streptozotocin-induced diabetic rats for 8 weeks before diabetic peripheral neuropathy developed or administrated therapeutically after diabetic peripheral neuropathy developed, respectively. The motor nerve conduction velocities (MNCV), aldose reductase (AR) activities, the polyol contents and antioxidative enzyme activities in the sciatic never tissues were determined. The morphology of sciatic never tissues was observed. Results In comparison to vehicle, most of the changes in the sciatic nerves of the diabetic rats (e. g., delayed MNCV, altered/damaged nerve structure, enhanced AR activity, increased polyol contents, altered Cu, Zn-superoxide dismutase, glutathione-peroxidase activities, and elevated malondialdehyde level) were significantly ameliorated by prophylactic administration with either GLZ or MCA. In contrast, only few of above-mentioned parameters were alleviated in DPN rats by therapeutic administration with GLZ or MCA as compared to vehicle. The curative effects of GLZ or MCA prophylactic administration on MNCV, AR activity, polyol contents and antioxidative enzyme activities were markedly stronger than therapeutic administration. Conclusion Prophylactic administration of GLZ or MCA was superior to the therapeutic administration in alleviation of diabetic neuropathy in STZ-rats, suggesting that pharmacotherapy should be initiated at a much earlier stage before diabetic neuropathy developed, but not at a later stage after never damage reached.

[1]  Qifu Li,et al.  Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double‐blind, controlled trial , 2016, Journal of diabetes investigation.

[2]  Wei Zhou,et al.  Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway , 2016, Neural regeneration research.

[3]  S. Tangvarasittichai Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. , 2015, World journal of diabetes.

[4]  B. Masola,et al.  Antioxidant Strategies in the Management of Diabetic Neuropathy , 2015, BioMed research international.

[5]  M. Babizhayev,et al.  Oxidative damage impact on aging and age-related diseases: drug targeting of telomere attrition and dynamic telomerase activity flirting with imidazole-containing dipeptides. , 2014, Recent patents on drug delivery & formulation.

[6]  J. Albers,et al.  Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes , 2014, Current Neurology and Neuroscience Reports.

[7]  A. Mima Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets , 2013, Journal of diabetes research.

[8]  M. Goulart,et al.  Oxidative Stress as an Underlying Contributor in the Development of Chronic Complications in Diabetes Mellitus , 2013, International journal of molecular sciences.

[9]  M. Ren,et al.  Protective effect of gliclazide on diabetic peripheral neuropathy through Drp-1 mediated-oxidative stress and apoptosis , 2012, Neuroscience Letters.

[10]  K. Martin,et al.  Aldose Reductase, Oxidative Stress, and Diabetic Mellitus , 2012, Front. Pharmacol..

[11]  Michael J. González,et al.  Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. , 2011, Current clinical pharmacology.

[12]  Ferdinando Giacco,et al.  Oxidative stress and diabetic complications. , 2010, Circulation research.

[13]  J. Tang,et al.  Validation of structural and functional lesions of diabetic retinopathy in mice , 2010, Molecular vision.

[14]  S. Chakrabarti Diabetic Retinopathy: From Pathogenesis to Treatment , 2008, Experimental Diabetes Research.

[15]  M. Lorenzi The Polyol Pathway as a Mechanism for Diabetic Retinopathy: Attractive, Elusive, and Resilient , 2007, Experimental diabetes research.

[16]  K. Head Peripheral neuropathy: pathogenic mechanisms and alternative therapies. , 2006, Alternative medicine review : a journal of clinical therapeutic.

[17]  B. Sancak,et al.  Lipid peroxidation and scavenging enzyme levels in the liver of streptozotocin-induced diabetic rats. , 2003, Indian journal of biochemistry & biophysics.

[18]  Sookja K. Chung,et al.  Contribution of polyol pathway to diabetes-induced oxidative stress. , 2003, Journal of the American Society of Nephrology : JASN.

[19]  T. Kizaki,et al.  Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide , 2003 .

[20]  E. Feldman,et al.  Update on diabetic neuropathy , 2002, Current opinion in neurology.

[21]  G. Kimura,et al.  Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  D. Greene,et al.  An aldose reductase inhibitor reverses early diabetes‐induced changes in peripheral nerve function, metabolism, and antioxidative defense , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  R. Pop-Busui,et al.  Depletion of Taurine in Experimental Diabetic Neuropathy: Implications for Nerve Metabolic, Vascular, and Functional Deficits , 2001, Experimental Neurology.

[24]  K. Sugimoto,et al.  Diabetic neuropathy – a continuing enigma , 2000, Diabetes/metabolism research and reviews.

[25]  A. Desfaits,et al.  Effect of gliclazide on monocyte-endothelium interactions in diabetes. , 2000, Journal of diabetes and its complications.

[26]  R. O’Brien,et al.  In vitro and in vivo antioxidant properties of gliclazide. , 2000, Journal of diabetes and its complications.

[27]  D. M. Morré,et al.  Surface oxidase and oxidative stress propagation in aging. , 2000, The Journal of experimental biology.

[28]  J. Belch,et al.  Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. , 2000, Metabolism: clinical and experimental.

[29]  K. Sugimoto,et al.  Experimental diabetic neuropathy: an update , 1999, Diabetologia.

[30]  S. Kuwabara,et al.  Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. , 1999, Internal medicine.

[31]  A. Desfaits,et al.  Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. , 1997, Metabolism: clinical and experimental.

[32]  K. Prasad,et al.  Antioxidant defense system in diabetic kidney: a time course study. , 1997, Life sciences.

[33]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[34]  J. Belch,et al.  Gliclazide: a general free radical scavenger. , 1991, European journal of pharmacology.

[35]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[36]  P. Bouček Advanced Diabetic Neuropathy: A Point of no Return? , 2006, The review of diabetic studies : RDS.

[37]  Feng juan Wei Effects of methylcobalamin,gliclazide and their combination on peripheral nerve function and polyol pathway in streptozotocin diabetic rats , 2004 .

[38]  J. Dunlap,et al.  Slowing of Motor Nerve Conduction Velocity in Streptozotocin-induced Diabetic Rats is Preceded by Impaired Vasodilation in Arterioles that Overlie the Sciatic Nerve , 2000, International journal of experimental diabetes research.

[39]  H. Aebi,et al.  Catalase in vitro. , 1984, Methods in enzymology.